Guidelines American Journal of Kidney Diseases   American Journal of Kidney Diseases  Volume 46, Pages 12-100 (October 2005) DOI: 10.1053/j.ajkd.2005.07.026 Copyright © 2005 Terms and Conditions

Fig 1 Relationship between Serum iPTH Levels and CCR. Values on the y-axis are serum iPTH levels (pg/mL). Values on the x-axis are CCR in mL/min. The lines fitted to the data set are based on 4 different mathematical functions (power, linear, exponential, and logarithmic), rather than on any assumptions about an underlying physiological mechanism. The horizontal line represents the upper limit of the normal range of serum iPTH levels. Reproduced with permision.21 American Journal of Kidney Diseases 2005 46, 12-100DOI: (10.1053/j.ajkd.2005.07.026) Copyright © 2005 Terms and Conditions

Fig 2 Summary ROC Analysis of Erosions on X-Ray as Diagnostic for Osteitis Fibrosa. Summary ROC derived from four individual studies assessing the diagnostic characteristics of erosions on X-ray for diagnosis of osteitis fibrosa. Values on the y-axis are the diagnostic sensitivity and values on the x-axis are the diagnostic specificity. The more effective the test is as a diagnostic, the closer it falls to the upper left hand corner of the graph. The summary ROC curve and its 95% confidence interval provide a summary estimate of the performance of the test based on the meta-analytically combined results from all four studies. The mean threshold point is our best single point estimate of the sensitivity and specificity of erosions on x-ray. In this case, the sensitivity for presence of erosions on x-ray as a tool for diagnosing osteitis fibrosa was 59.8% (95% CI: 44.9-73.2) and specificity was 79.9% (95% CI: 63.2-85.2). American Journal of Kidney Diseases 2005 46, 12-100DOI: (10.1053/j.ajkd.2005.07.026) Copyright © 2005 Terms and Conditions

Fig 3 Summary ROC Analysis of Intact PTH for Diagnosis of High-Turnover Bone Disease. Summary ROC derived from six individual studies assessing the diagnostic characteristics of iPTH levels for the diagnosis of high-turnover bone disease. Values on the y-axis are the diagnostic sensitivity and values on the x-axis are the diagnostic specificity. The more effective the test is as a diagnostic tool, the closer it falls to the upper left hand corner of the graph. The summary ROC curve and 95% CI provide a summary estimate of the performance of the test based on the meta-analytically combined results from all five studies. The mean threshold (indicated in the graph by a diamond icon) is the best point estimate of the sensitivity and specificity of iPTH levels for the diagnosis of high-turnover bone disease. American Journal of Kidney Diseases 2005 46, 12-100DOI: (10.1053/j.ajkd.2005.07.026) Copyright © 2005 Terms and Conditions

Fig 4 Summary ROC Analysis of Intact PTH for Diagnosis of Low-Turnover Bone Disease. Summary ROC derived from five individual studies assessing the diagnostic characteristics of iPTH levels for the diagnosis of low-turnover bone disease. Values on the y-axis are the diagnostic sensitivity and values on the x-axis are the diagnostic specificity. The more effective the test is as a diagnostic, the closer it falls to the upper left hand corner of the graph. The summary ROC curve and its 95% CI provide a summary estimate of the performance of the test based on the meta-analytically combined results from all five studies. The mean threshold (indicated in the graph by a diamond icon) is the best point estimate of the sensitivity and specificity of iPTH levels for the diagnosis of low-turnover bone disease. American Journal of Kidney Diseases 2005 46, 12-100DOI: (10.1053/j.ajkd.2005.07.026) Copyright © 2005 Terms and Conditions

Fig 5 Meta-Analysis of Size of Effect on Serum Phosphorus Levels of Calcium Acetate versus Calcium Carbonate American Journal of Kidney Diseases 2005 46, 12-100DOI: (10.1053/j.ajkd.2005.07.026) Copyright © 2005 Terms and Conditions

Fig 6 Meta-Analysis of Size of Hypercalcemic Effect of Calcium Carbonate versus Other Phosphate Binders American Journal of Kidney Diseases 2005 46, 12-100DOI: (10.1053/j.ajkd.2005.07.026) Copyright © 2005 Terms and Conditions

Fig 7 Meta-Analysis of Oral versus Intravenous Calcitriol on PTH Suppression American Journal of Kidney Diseases 2005 46, 12-100DOI: (10.1053/j.ajkd.2005.07.026) Copyright © 2005 Terms and Conditions

Fig 8 Individual Study and Summary Effect Sizes for the Effect of DFO Therapy on Bone Formation Rate American Journal of Kidney Diseases 2005 46, 12-100DOI: (10.1053/j.ajkd.2005.07.026) Copyright © 2005 Terms and Conditions

Fig 9 Individual Study and Summary Effect Sizes for the Effect of DFO Therapy on Bone Surface Aluminum Stain American Journal of Kidney Diseases 2005 46, 12-100DOI: (10.1053/j.ajkd.2005.07.026) Copyright © 2005 Terms and Conditions

Algorithm 1 Vitamin D Supplementation in CKD (Stages 2-4) American Journal of Kidney Diseases 2005 46, 12-100DOI: (10.1053/j.ajkd.2005.07.026) Copyright © 2005 Terms and Conditions

Algorithm 2 Management of CKD Patients (Stages 2-4) with Active Vitamin D Sterols American Journal of Kidney Diseases 2005 46, 12-100DOI: (10.1053/j.ajkd.2005.07.026) Copyright © 2005 Terms and Conditions

Algorithm 3 Managing Vitamin D Sterols Based on Serum Calcium Levels American Journal of Kidney Diseases 2005 46, 12-100DOI: (10.1053/j.ajkd.2005.07.026) Copyright © 2005 Terms and Conditions

Algorithm 4 Managing Vitamin D Sterols Based on Serum Phosphorus Levels American Journal of Kidney Diseases 2005 46, 12-100DOI: (10.1053/j.ajkd.2005.07.026) Copyright © 2005 Terms and Conditions

Algorithm 5 Managing Vitamin D Sterols Based on PTH Levels in Children Not Receiving Growth Hormones American Journal of Kidney Diseases 2005 46, 12-100DOI: (10.1053/j.ajkd.2005.07.026) Copyright © 2005 Terms and Conditions

Algorithm 6 Evaluation of Aluminum Neurotoxicity American Journal of Kidney Diseases 2005 46, 12-100DOI: (10.1053/j.ajkd.2005.07.026) Copyright © 2005 Terms and Conditions

Algorithm 7 Evaluation of Aluminum-Related Disorders: Considerations for DFO Test and Subsequent DFO Treatment American Journal of Kidney Diseases 2005 46, 12-100DOI: (10.1053/j.ajkd.2005.07.026) Copyright © 2005 Terms and Conditions

Algorithm 8 DFO Treatment After PAl Rise between 50-300 μg/L American Journal of Kidney Diseases 2005 46, 12-100DOI: (10.1053/j.ajkd.2005.07.026) Copyright © 2005 Terms and Conditions

Algorithm 9 Subsequent DFO Treatment after PAl Rise ≥300 μg/L American Journal of Kidney Diseases 2005 46, 12-100DOI: (10.1053/j.ajkd.2005.07.026) Copyright © 2005 Terms and Conditions

American Journal of Kidney Diseases 2005 46, 12-100DOI: (10. 1053/j American Journal of Kidney Diseases 2005 46, 12-100DOI: (10.1053/j.ajkd.2005.07.026) Copyright © 2005 Terms and Conditions

American Journal of Kidney Diseases 2005 46, 12-100DOI: (10. 1053/j American Journal of Kidney Diseases 2005 46, 12-100DOI: (10.1053/j.ajkd.2005.07.026) Copyright © 2005 Terms and Conditions

American Journal of Kidney Diseases 2005 46, 12-100DOI: (10. 1053/j American Journal of Kidney Diseases 2005 46, 12-100DOI: (10.1053/j.ajkd.2005.07.026) Copyright © 2005 Terms and Conditions